Revolution Medicines (RVMD) GC receives 32,500-option and 14,500-share grants

Rhea-AI Filing Summary

Revolution Medicines, Inc. reported that General Counsel Jeff Cislini received equity awards. He was granted a stock option for 32,500 shares at an exercise price of $0.00 and an award of 14,500 shares of common stock. The option vests in equal monthly installments over four years starting on March 1, 2026, becoming fully vested on the fourth anniversary, subject to his continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Cislini Jeff

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,500	$0.00	--
Grant/Award	Common Stock	14,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,500 shares (Direct); Common Stock — 61,476 shares (Direct)

Footnotes (1)

1. Includes 53,269 restricted stock units. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cislini Jeff

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		14,500	A	$0	61,476(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$102.02	03/01/2026		A		32,500		(2)	02/28/2036	Common Stock	32,500	$0	32,500	D

Explanation of Responses:

1. Includes 53,269 restricted stock units.

2. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

	/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did RVMD General Counsel Jeff Cislini report?

Jeff Cislini reported acquiring a stock option for 32,500 shares of Revolution Medicines and an award of 14,500 shares of common stock, both at a $0.00 price, reflecting equity compensation rather than open-market purchases.

How many Revolution Medicines (RVMD) shares are covered by the new stock option grant?

The new stock option grant covers 32,500 shares of Revolution Medicines common stock. According to the filing, this option was awarded at an exercise price of $0.00 per share and is subject to a specified four-year monthly vesting schedule starting March 1, 2026.

What common stock award did RVMD’s General Counsel receive in this Form 4?

The Form 4 shows Jeff Cislini received an award of 14,500 shares of Revolution Medicines common stock. These shares were acquired at a reported price of $0.00 per share, indicating a compensatory grant rather than an open-market stock purchase.

How does the stock option granted to RVMD’s General Counsel vest over time?

The stock option vests in 1/48 increments each month, starting on March 1, 2026. As disclosed, 100% of the 32,500 option shares will be fully vested and exercisable by the fourth anniversary, contingent on Jeff Cislini’s continued service through each vesting date.

What is the total RVMD share ownership reported after these transactions?

Following the reported grants, Jeff Cislini’s direct ownership in Revolution Medicines common stock is 61,476 shares. A footnote explains this total includes 53,269 restricted stock units, which represent rights to receive shares subject to vesting and other conditions.

What does the Form 4 reveal about restricted stock units held by RVMD’s General Counsel?

The Form 4 notes that Jeff Cislini’s reported holdings include 53,269 restricted stock units. Restricted stock units are rights to receive shares of common stock in the future, typically upon satisfaction of vesting conditions and any other requirements specified in the company’s equity plans.